Enzymatica is a life science company that develops products against infectious diseases based on the company's barrier technology with marine enzymes. The Lund company has developed ColdZyme, A mouth spray that protects against cold viruses by creating a protective barrier in the oral cavity and throat.
Earlier this year was appointed Claus Egstrand to CEO of Enzymatica after having been COO of the company for a long time. The original schedule was that Claus Egstrand would take up his position no later than January 1, 2022, but now Enzymatica announces that he will take up the role as CEO already today, September 9. This is because his other commitments have been completed, which means that he is already ready to take on the role as CEO.
Part of the company since 2017
Claus Egstrand has extensive experience from large pharmaceutical and medical technology companies such as Merck & Co, Pfizer, Stryker Corporation, Pharmacia and Johnson & Johnson/Merck Pharmaceuticals.
Claus has worked for Enzymatica since 2017, first as Chief Commercial Officer and then as Chief Operating Officer. During his four years with the company, he has played a crucial role in the company's international growth by concluding distributor agreements for several new markets. Claus will also devote a large part of his time to Enzymatica's international expansion, which he looks forward to, according to a press release:
»Enzymatica is only at the beginning of its growth journey. I am really looking forward to developing the business into a fully-fledged international life science company together with all the competent employees«
Filmersson and Baron return to their roles
With the new CEO in place, the acting CEO will Therese Filmersson return to the role of CFO after having been acting CEO since June 2020. She will also assume the role of vice president of the company. In addition, Bengt Baron return to his previous role as Chairman of the Board from having been the acting Chairman of the Board of Enzymatica.
Patent applications in the US and China pave the way for further expansion
A message that will facilitate Egstrand's expansion plans was announced in August when the patent offices in the US and China announced that they intend to grant patents for the enzyme cod trypsin, which is an important key component in ColdZyme. The patents in the US and China are valid until 2036, which gives Enzymatica a strong position in these two important markets, according to Claus Egstrand:
»The patents in China and the USA give ColdZyme and other products based on the same technology platform a strong position in both markets. The two granted patents are important messages for Enzymatica's continued international expansion – Claus Egstrand«
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.